TRANSEPITHELIAL TRANSPORT OF INSULIN .1. INSULIN DEGRADATION BY INSULIN-DEGRADING ENZYME IN SMALL-INTESTINAL EPITHELIUM

被引：35

作者：

BAI, JPF

CHANG, LL

机构：

[1] Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota

来源：

PHARMACEUTICAL RESEARCH | 1995年 / 12卷 / 08期

关键词：

INSULIN-DEGRADING ENZYME; MONOCLONAL ANTIBODY TO IDE; IDE INHIBITORS;

D O I：

10.1023/A:1016263926946

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Purpose. The purpose of this study was to determine the existence of insulin-degrading enzyme (EC 3.4.22.11) (IDE) in rat intestinal enterocytes. Methods. Subcellular fractionation, biochemical characterization, immunoprecipitation, and western blots were employed. Results. Insulin-degrading activity was localized in the cytosol, constituting 92% of total insulin-degrading activity. Cytosolic insulin-degrading activity had a pH optimum of 7.5, was almost completely inhibited by IDE inhibitors (N-ethylmaleimide, 1,10-phenanthroline, EDTA, p-chloromercuribenzoate, bacitracin), but was not or only weakly inhibited by others (aprotinin, chmyostatin, leupeptin, and diisopropyl phosphofluoridate.) Further, cytosolic insulin-degrading activity had a Km of 78 nM, sharing a similar Km value with insulin-degrading enzyme in non-purified forms. Approximately, 87 +/- 1.7% of cytosolic insulin-degrading activity was removed by the monoclonal antibody to IDE. On the SDS gel, the molecular weight of cytosolic IDE was 110 KD which is the same as that of human IDE. Conclusions. IDE is the major enzyme which degrades insulin in enterocytes.

引用

页码：1171 / 1175

页数：5

共 29 条

[1] Vlahos W.D., Seemayer T.A., Yale J.F., Diabetes prevention in BB rats by inhibition of endogenous insulin secretion, Metab., 40, pp. 825-829, (1991)
[2] Shao Z., Li Y., Krishnamoorthy R., Chermak T., Mitra. A.K., Differential effects of anionic, cationic, nonionic, and physiologic surfactant on the dissociation, α-chymotryptic degradation, and enteral absorption of insulin hexamers, Pharm. Res., 10, pp. 243-250, (1993)
[3] Fujii S., Yokoyama T., Ikegaya T.K., Sato F., Yokoo. N., Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs, J. Pharm. Pharmacol., 37, pp. 545-549, (1985)
[4] Schilling R.J., Mitra A.K., Degradation of insulin by trypsin and alpha-chymotrypsin, Pharm. Res., 8, pp. 721-727, (1991)
[5] Yamamoto A., Hayakawa E., Lee. V.H.L., Insulin and proinsulin proteolysis in mucosal homogenates of the rabbit: implications in peptide delivery from nonoral routes, Life Sci., 47, pp. 2465-2474, (1990)
[6] Duckworth W.C., Insulin degradation:mechanisms, products, and significance, Rev., 9, pp. 319-345, (1988)
[7] Duckworth W.C., Insulin degrading enzyme, Insulin, (1990)
[8] Kuo W.L., Montag A.G., Rosner M.R., Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues, Endocrinol., 132, pp. 604-611, (1993)
[9] Pillion D.J., Ganapathy V., Leibach F.H., Identification of insulin receptors on the mucosal surface of colon epithelial cells, J. Biol. Chem., 260, pp. 5244-5247, (1985)
[10] Gingerich R.L., Gilbert W.R., Comens P.G., Gavin . J.R., Identification and characterization of insulin receptors in basolateral membranes of dog intestinal mucosa, Diabetes, 36, pp. 1124-1129, (1987)

← 1 2 3 →